ArticleScientific reports2025
Circulating biomarkers and neuroanatomical brain structures differ in older adults with and without post-traumatic stress disorder.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to advance post-traumatic stress disorder (PTSD) understanding in older adults (48-77 years) by determining if circulating cytokines (IL-1β, IL-2, IL-4, IL-6, IL-12p70, IL17A and TNFα), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF-A) and neuroanatomical brain volumes (grey and white matter, hippocampus, and amygdala) significantly differed in those with versus without PTSD. While none of the tested cytokines showed a significant difference, serum BDNF and VEGF-A levels were found to be significantly higher in the PTSD cohort. The assay used for BDNF quantification was important, with differences in general BDNF detected, but not when pro- and mature BDNF were measured specifically. Additionally, BDNF genotyping revealed a significant difference in Val66Met genotype distribution by PTSD diagnosis, with Val66Met carriers generally having lower circulating levels of BDNF compared to their Val66Val counterparts, regardless of PTSD diagnosis. Neuroanatomically, an all-female subset was examined to find total grey and white matter volumes and left and right hippocampal volumes were significantly smaller in those with PTSD. Collectively, these results show that both novel (VEGF-A) and established targets (BDNF and neuroimaging) may serve as useful biomarkers for older adults with PTSD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.